Core Viewpoint - Berberine shows potential as a long-term preventive agent for colorectal adenoma recurrence after polypectomy, with significant reductions in recurrence and neoplasm occurrence rates observed in clinical studies [4][6][8]. Group 1: Study Findings - A recent study indicated that berberine treatment resulted in a lower adenoma recurrence rate of 34.7% compared to 52.1% in the control group, and a lower tumor occurrence rate of 63.4% versus 71.0% after a follow-up period of at least 6 years [4][7]. - In a previous two-year randomized clinical trial, berberine significantly reduced the recurrence rate of colorectal adenomas to 36% compared to 47% in the placebo group, with no serious adverse events reported [6][9]. - The long-term protective effect of berberine was confirmed in a retrospective cohort study that followed up on participants from the initial trial, demonstrating sustained benefits post-treatment [7][8]. Group 2: Research Background - The study on berberine was conducted by a team from Shanghai Jiao Tong University School of Medicine and published in Cell Reports Medicine, extending the follow-up of a prior clinical trial [4][6]. - The initial trial involved 895 patients, with 781 participants recruited for the follow-up study, which assessed the long-term effects of berberine on adenoma recurrence [7][8].